A Case Study of Unity Biotechnology and The Volatility of The Stock Market

Photo of author
Written By Dean McHugh

Investing in the stock market is a journey filled with highs and lows, opportunities for significant gains, and the risk of losses. One of the most straightforward strategies for capitalizing on market growth is investing in index funds, which offer broad market exposure, reducing the risk of individual stock underperformance.

However, the allure of potentially higher returns from individual stocks comes with its own set of challenges, as demonstrated by Unity Biotechnology, Inc. (NASDAQ: UBX) investors over the past year.

Read More: Chemours Remains Resilient in The Face of Challenges

The High Stakes of Individual Investments

Unity Biotechnology, a company operating in the biotechnology sector, has seen its share price plummet by 45% over the last year, starkly contrasting with the broader market’s 23% gain.

Credits: DepositPhotos

This decline highlights the volatility and risk inherent in investing in individual stocks, especially those of companies recently listed or with unproven market performance. The past month alone saw a further 13% decrease in Unity’s share price, indicating continuing negative momentum.

Financial Performance and Market Speculation

A closer examination of Unity Biotechnology’s financial health reveals a revenue of just US$1,382,000 in the last twelve months.

Such a modest sum raises questions about the company’s product viability and its ability to secure venture capital funding.

This situation suggests that investors might be less focused on current earnings and more on speculative growth potential.

The hope among some investors is likely that Unity Biotechnology will successfully innovate and launch a new product in the near future, despite the current financial indicators suggesting high risk.

Also Read: Deciphering 4D Molecular Therapeutics’ Market Movements

The Risk-Reward Equation

Investing in companies that lack significant revenue or profit is inherently risky. There’s always a possibility these companies will need to issue more shares to fund their operations, diluting current shareholder value.

While some of these ventures eventually succeed and provide substantial returns, others may succumb to market pressures, leading to significant losses or even bankruptcy.

As of September 2019, Unity Biotechnology reported having cash reserves exceeding its liabilities by US$86 million.

This financial cushion, however, does not eliminate the risk of additional capital raising, especially if profitability remains elusive. This concern is reflected in the company’s share price, which has suffered a significant decline over the past year.

Insider Movements and Investor Sentiment

For investors, the actions of company insiders can provide valuable clues about a company’s future prospects.

Credits: DepositPhotos

In the case of Unity Biotechnology, the absence of revenue makes it difficult to assess the company’s value through conventional metrics. Consequently, investors might be particularly attuned to insider stock transactions.

A scenario where insiders are selling shares could further erode investor confidence, likened humorously to the undesirable mix of milk and fruit juice.

A Broader Perspective on Investment Performance

While Unity Biotechnology’s investors have faced a challenging year, it’s important to remember that the stock market is a long-term play. Even the best investments can undergo periods of underperformance.

The ongoing decline in Unity’s share price, including a 6.9% drop over the last three months, points to a lack of investor enthusiasm. Caution is advised when considering investment in stocks that have not demonstrated a capacity for strong performance.

Final Thoughts

Investing in the stock market, particularly in individual stocks like Unity Biotechnology, requires a careful balance of risk and reward.

The company’s journey underscores the importance of due diligence and the need to monitor a range of indicators, including insider actions and financial health. For those considering such investments, it’s crucial to stay informed and be prepared for the volatility that comes with the territory.

Read Next: Gain Therapeutics Welcomes New Chief Medical Officer


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.